14
Participants
Start Date
August 31, 2013
Primary Completion Date
June 30, 2016
Study Completion Date
October 31, 2016
Dovitinib and docetaxel
"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
Asan Medical Center, Seoul
Lead Sponsor
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Asan Medical Center
OTHER